PFE Stock Forecast: Pfizer Inc. Price Predictions for 2026-2027
The 28 Wall Street analysts covering Pfizer Inc. hold a median 12-month price target of $30 — +9.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 91 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Pfizer Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PFE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PFE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.4% from it.
Of the 20 most recent actions, 10 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Nov 2026 | Freedom Broker | Maintains | Buy | — |
| 6 Nov 2026 | Freedom Broker | Maintains | Buy | $33 → $34 |
| 5 Nov 2026 | Guggenheim | Maintains | Buy | $31 → $33 |
| 4 Nov 2026 | Citigroup | Maintains | Neutral | $27 → $30 |
| 4 Nov 2026 | RBC Capital | Maintains | Sector Perform | $25 → $28 |
| 4 Nov 2026 | Scotiabank | Maintains | Sector Outperform | $33 → $35 |
| 4 Nov 2026 | UBS | Maintains | Neutral | $27 → $30 |
| 9 Oct 2026 | JP Morgan | Maintains | Neutral | $28 → $30 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $27 → $28 |
| 6 Oct 2026 | Scotiabank | Maintains | Sector Outperform | $30 → $33 |
| 10 Sept 2026 | HSBC | Maintains | Hold | $28 → $30 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $35 → $31 |
| 13 July 2026 | BMO Capital | Maintains | Outperform | $34 → $30 |
| 13 July 2026 | Guggenheim | Maintains | Buy | $36 → $35 |
| 10 July 2026 | B of A Securities | Maintains | Neutral | $27 → $26 |
| 8 July 2026 | JP Morgan | Maintains | Neutral | $30 → $28 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | $27 |
| 6 July 2026 | HSBC | Downgrade | Hold | $32 → $28 |
| 10 June 2026 | RBC Capital | Upgrade | Sector Perform | — |
| 29 Apr 2026 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PFE.
This page is one stock. Monday covers all of them.
PFE appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PFE vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Pfizer Inc. returned +19.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PFE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 40.1×
- Price / sales
- 2.5×
- Price / book
- 1.8×
- EV / EBITDA
- 8.3×
Cheaper than 21% of US stocks
Cheaper than 42% of US stocks
Cheaper than 48% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- −0.4%
- Earnings growth (YoY)
- −8.4%
- Gross margin
- 72.8%
- Operating margin
- 29.1%
- Net margin
- 6.3%
Higher than 28% of US stocks
Higher than 27% of US stocks
Higher than 85% of US stocks
Higher than 87% of US stocks
Higher than 60% of US stocks
- Return on equity
- 4.5%
- Return on assets
- 5.6%
- Dividend yield
- 6.2%
Higher than 51% of US stocks
Higher than 79% of US stocks
Higher than 84% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pfizer Inc. has a market value of $157.0B and an enterprise value of $206.4B.
Revenue in the twelve months to 30 June 2026: $63.7B. The latest quarter grew 2.6% year on year.
Net income over the same four quarters: $4.4B, a 6.9% net margin.
Diluted earnings per share, trailing twelve months: $0.76.
Free cash flow in the twelve months to 30 June 2026: $11.0B.
Pfizer Inc. spent $9.8B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 40.1×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 6.24%, paying out 246% of earnings.
Pfizer Inc. employs 75,000 people — $849K of revenue per employee.
Data provided by Twelve Data
PFE and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PFE’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Pfizer Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PFE
What is the PFE stock price forecast for 2026-2027?
The 28 Wall Street analysts covering Pfizer Inc. have a median 12-month price target of $30, with estimates ranging from $25 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PFE stock a buy right now?
Of the 28 analysts covering Pfizer Inc., 9 rate it a Buy, 17 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Pfizer Inc. 91 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PFE?
As at 21 Nov 2026, Pfizer Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
Will PFE stock go up?
No one can know that. What the data says: the median 12-month target from 28 analysts implies +9.4% from the last close, and Ticker Nerd's factor model ranks Pfizer Inc. 91 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PFE stock forecast for 2030?
No analyst covering Pfizer Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $37 over the next 12 months.
How has PFE stock performed over the past year?
Pfizer Inc. returned +19.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pfizer Inc. do?
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems.
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets. The company plays a central role in global healthcare by supplying prescription therapies and immunizations across major therapeutic areas, while its research and development organization continues to support the launch, approval, and lifecycle management of new treatments. Founded in 1849 and headquartered in New York City, Pfizer Inc. remains one of the most recognized names in the pharmaceutical industry.
CEO Dr. Albert Bourla D.V.M., Ph.D. · 75,000 employees · United States · https://www.pfizer.com